28. Systemic amyloidosis Clinical trials / Disease details

Clinical trials : 261 / Drugs : 276 - (DrugBank : 81) / Drug target genes : 68 - Drug target pathways : 178

27 trials found

diseases per page:

Showing 1 to 10 of 27 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-002639-48-ES (EUCTR)	08/03/2022	28/12/2021	A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain ...	A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain ...	Amyloid Light Chain Amyloidosis MedDRA version: 23.0;Level: LLT;Classification code 10083938;Term: A ...	Trade Name: DAZARLEX Product Name: Daratumumab co-formulated with recombinant human hyaluronidase (rHu ...	Janssen-Cilag International N.V.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 2	France;United States;Greece;Canada;Spain;Netherlands;Germany;United Kingdom;Italy
2	NCT04895917 (ClinicalTrials.gov)	June 23, 2021	10/5/2021	Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis	A Multi-center Open Label Phase II Study of Daratumumaband Pomalidomide in Previously Treated Patien ...	AL Amyloidosis	Drug: daratumumab and pomalidomide	IRCCS Policlinico S. Matteo	NULL	Recruiting	18 Years	99 Years	All	40	Phase 2	Italy
3	NCT04270175 (ClinicalTrials.gov)	April 14, 2021	12/2/2020	Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Pa ...	Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Pa ...	Amyloid;AL Amyloidosis;Refractory AL Amyloidosis	Drug: Daratumumab;Drug: Pomalidomide;Drug: Dexamethasone	Weill Medical College of Cornell University	Janssen Scientific Affairs, LLC	Recruiting	18 Years	N/A	All	21	Phase 2	United States
4	EUCTR2019-001962-13-IT (EUCTR)	13/01/2021	21/10/2020	Daratumumab and Pomalidomide in previously treated patients with AL amyloidosis	A multi-center open label phase II study of daratumumaband pomalidomide in previously treated patien ...	AL amyloidosis MedDRA version: 20.0;Level: PT;Classification code 10002022;Term: Amyloidosis;System ...	Trade Name: Imnovid Product Name: Pomalidomide Product Code: [Pomalidomide] INN or Proposed INN: pomali ...	FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	Italy
5	NCT04304144 (ClinicalTrials.gov)	March 18, 2020	28/2/2020	A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis	CAEL101-203: A Phase 2, Open-label, Multicenter Dose Selection Study to Evaluate the Safety and Tole ...	AL Amyloidosis	Drug: CAEL-101;Drug: cyclophosphamide , bortezomib, and Dexamethasone (CyBorD);Drug: Daratumumab	Caelum Biosciences	NULL	Active, not recruiting	18 Years	N/A	All	25	Phase 2	United States
6	EUCTR2018-004333-33-FR (EUCTR)	23/01/2020	02/12/2019	Phase 2 study of daratumumabmonotherapy in previously untreated patients with stage 3B light chain ( ...	Phase 2 study of daratumumabmonotherapy in previously untreated patients with stage 3B light chain ( ...	Patients with newly diagnosed stage 3B AL amyloidosis MedDRA version: 20.0;Level: PT;Classification ...	Trade Name: Velcade Product Name: Bortezomib Product Code: 26866138 INN or Proposed INN: BORTEZOMIB Prod ...	European Myeloma Network	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	France;Greece;Netherlands;Italy
7	EUCTR2018-004333-33-IT (EUCTR)	01/08/2019	28/04/2020	Phase 2 study of daratumumabmonotherapy in previously untreated patients with stage 3B light chain ( ...	Phase 2 study of daratumumabmonotherapy in previously untreated patients with stage 3B light chain ( ...	Patients with newly diagnosed stage 3B AL amyloidosis MedDRA version: 20.0;Level: PT;Classification ...	Trade Name: Darzalex Product Name: Daratumumab Product Code: JNJ-54767414 INN or Proposed INN: DARATUMU ...	European Myeloma Network	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	France;Greece;Netherlands;Italy
8	EUCTR2018-004333-33-NL (EUCTR)	24/07/2019	08/07/2019	Phase 2 study of daratumumabmonotherapy in previously untreated patients with stage 3B light chain ( ...	Phase 2 study of daratumumabmonotherapy in previously untreated patients with stage 3B light chain ( ...	Patients with newly diagnosed stage 3B AL amyloidosis MedDRA version: 20.0;Level: PT;Classification ...	Trade Name: Darzalex Product Name: Daratumumab Product Code: JNJ-54767414 INN or Proposed INN: DARATUMU ...	European Myeloma Network	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	France;Greece;Netherlands;Italy
9	EUCTR2018-004333-33-GR (EUCTR)	08/07/2019	05/06/2019	Phase 2 study of daratumumabmonotherapy in previously untreated patients with stage 3B light chain ( ...	Phase 2 study of daratumumabmonotherapy in previously untreated patients with stage 3B light chain ( ...	Patients with newly diagnosed stage 3B AL amyloidosis MedDRA version: 20.0;Level: PT;Classification ...	Trade Name: Darzalex Product Name: Daratumumab Product Code: JNJ-54767414 INN or Proposed INN: DARATUMU ...	European Myeloma Network	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	France;Greece;Netherlands;Italy
10	EUCTR2016-001737-27-GB (EUCTR)	08/10/2018	11/01/2018	A Study to Evaluate the Efficacy and Safety of Daratumumabin Combination With Cyclophosphamide, Bort ...	A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumabin Combination with Cyc ...	AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis ) MedDRA version: 20.0;Level: PT;Classificat ...	Product Name: Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20) Product Code: J ...	Janssen-Cilag International N.V.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	370	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	United States;Greece;Spain;Turkey;Israel;Italy;United Kingdom;France;Hungary;Mexico;Canada;Poland;Be ...

First Previous1 2 3Next Last